Short Bowel Syndrome Market Growth Projections 2024-2034: DelveInsight Analysis | Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma

The Key Short Bowel Syndrome Companies in the market include - Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others.

DelveInsight's "Short Bowel Syndrome Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Short Bowel Syndrome, historical and forecasted epidemiology as well as the Short Bowel Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Short Bowel Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Short Bowel Syndrome Market Forecast [https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Short Bowel Syndrome Market Report:

*
The Short Bowel Syndrome market size was valued approximately USD 2.3 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In March 2025, Ironwood Pharmaceuticals (Nasdaq: IRWD) was a biotechnology company dedicated to developing and commercializing transformative therapies for individuals with gastrointestinal (GI) and rare diseases. The company is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog designed for short bowel syndrome patients reliant on parenteral support. Additionally, Ironwood has been instrumental in developing LINZESS Registered (linaclotide), the leading U.S. prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

*
In December 2024, Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology company specializing in peptide-based medicines, announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for glepaglutide. The long-acting GLP-2 analog is being developed to treat adult patients with short bowel syndrome (SBS) and intestinal failure (IF) who rely on parenteral support.

*
In February 2024, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a company specializing in gastrointestinal healthcare, has unveiled promising top-line outcomes from its pivotal Phase III STARS trial. This trial assessed the effectiveness and safety of subcutaneous apraglutide administered once weekly in reducing the dependency on parenteral support (PS) in adult patients diagnosed with short bowel syndrome with intestinal failure (SBS-IF). SBS-IF is a rare and severe condition resulting in organ failure, where patients rely on PS. Approximately 18,000 adult patients in the United States, Europe, and Japan are affected by this condition. Following these findings, Ironwood intends to submit a new drug application (NDA) and other regulatory documents for apraglutide aimed at treating adult SBS patients reliant on PS.

*
In 2023, the total market size for Short Bowel Syndrome in the US was estimated to be approximately USD 2,000 million, with Japan following closely behind.

*
In 2022, the United States reported the highest number of cases among the seven major markets, with a prevalence of 20,800 cases.

*
In 2022, Germany had the highest prevalence of Short Bowel Syndrome cases among the European Union Four (EU4) and the United Kingdom, with approximately 2,700 reported cases.

*
According to information released by the Crohn's & Colitis Foundation of America, an estimated 10,000 to 20,000 individuals in the United States are affected by Short Bowel Syndrome.

*
According to information provided by PINNT, approximately 1,000 individuals in England are believed to have Short Bowel Syndrome, necessitating ongoing treatment with parenteral nutrition support.

*
Emerging therapies for Short Bowel Syndrome (SBS) comprise Glepaglutide, Apraglutide, HM15912, and various others. Ongoing research suggests the potential development of enhanced pharmacologic treatments targeting improved intestinal adaptation, regulation of gut motility, management of small bowel bacterial overgrowth, and addressing rejection issues following small intestinal transplantation.

*
Key Short Bowel Syndrome Companies: Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others

*
Key Short Bowel Syndrome Therapies: Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others

*
The Short Bowel Syndrome epidemiology based on gender analyzed that Short Bowel Syndrome affects females more than males

*
The Short Bowel Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Short Bowel Syndrome pipeline products will significantly revolutionize the Short Bowel Syndrome market dynamics.

Short Bowel Syndrome Overview

Short Bowel Syndrome (SBS), also known as short gut syndrome, is a complex disorder that occurs when a significant portion of the small intestine is missing or nonfunctional. The small intestine is responsible for absorbing nutrients from the food we eat into the bloodstream. When a substantial portion of it is surgically removed due to conditions like Crohn's disease, ischemic bowel disease, or traumatic injury, it can result in SBS.

Get a Free sample for the Short Bowel Syndrome Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/short-bowel-syndrome-market [https://www.delveinsight.com/report-store/short-bowel-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Short Bowel Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Short Bowel Syndrome Epidemiology Segmentation:

The Short Bowel Syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Short Bowel Syndrome

*
Prevalent Cases of Short Bowel Syndrome by severity

*
Gender-specific Prevalence of Short Bowel Syndrome

*
Diagnosed Cases of Episodic and Chronic Short Bowel Syndrome

Download the report to understand which factors are driving Short Bowel Syndrome epidemiology trends @ Short Bowel Syndrome Epidemiology Forecast [https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Short Bowel Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Short Bowel Syndrome market or expected to get launched during the study period. The analysis covers Short Bowel Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Short Bowel Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Short Bowel Syndrome Therapies and Key Companies

*
Glepaglutide: Zealand Pharma

*
Apraglutide: Ironwood Pharmaceuticals

*
HM15912: Hanmi Pharmaceutical

*
Teduglutide: Shire

*
Pancreatic Enzyme: AbbVie

*
HM15912 Active: Hanmi Pharma

*
Somatropin: EMD Serono

*
ZP1848: Zealand Pharma

*
FE203799: VectivBio AG

*
Clinolipid: Baxter Healthcare

Discover more about therapies set to grab major Short Bowel Syndrome market share @ Short Bowel Syndrome Treatment Landscape [https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Short Bowel Syndrome Market Strengths

*
In the treatment of short bowel syndrome, GLP-2 and the long-acting GLP-2 analog are effective in improving fluid absorption. Recent clinical trials demonstrate that this can translate into meaningful reductions in parenteral nutrition requirements.

*
Current treatments are effective in relieving the symptoms and improving the quality of life of the patients

Short Bowel Syndrome Market Opportunities

*
Several organizations are actively working to provide information and increase awareness of such disorders.

*
There are less treatment options for Short bowel syndrome which opens a platform of new therapies to boost the market of Short bowel syndrome

Scope of the Short Bowel Syndrome Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Short Bowel Syndrome Companies: Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others

*
Key Short Bowel Syndrome Therapies: Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others

*
Short Bowel Syndrome Therapeutic Assessment: Short Bowel Syndrome current marketed and Short Bowel Syndrome emerging therapies

*
Short Bowel Syndrome Market Dynamics: Short Bowel Syndrome market drivers and Short Bowel Syndrome market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Short Bowel Syndrome Unmet Needs, KOL's views, Analyst's views, Short Bowel Syndrome Market Access and Reimbursement

To know more about Short Bowel Syndrome companies working in the treatment market, visit @ Short Bowel Syndrome Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Short Bowel Syndrome Market Report Introduction

2. Executive Summary for Short Bowel Syndrome

3. SWOT analysis of Short Bowel Syndrome

4. Short Bowel Syndrome Patient Share (%) Overview at a Glance

5. Short Bowel Syndrome Market Overview at a Glance

6. Short Bowel Syndrome Disease Background and Overview

7. Short Bowel Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Short Bowel Syndrome

9. Short Bowel Syndrome Current Treatment and Medical Practices

10. Short Bowel Syndrome Unmet Needs

11. Short Bowel Syndrome Emerging Therapies

12. Short Bowel Syndrome Market Outlook

13. Country-Wise Short Bowel Syndrome Market Analysis (2020-2034)

14. Short Bowel Syndrome Market Access and Reimbursement of Therapies

15. Short Bowel Syndrome Market Drivers

16. Short Bowel Syndrome Market Barriers

17. Short Bowel Syndrome Appendix

18. Short Bowel Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=short-bowel-syndrome-market-growth-projections-20242034-delveinsight-analysis-zealand-pharma-ironwood-pharmaceuticals-hanmi-pharmaceutical-shire-abbvie-hanmi-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.